UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/791,219	03/02/2004	Lois Weisman	IOWA:048US	3887
Steven L. Highl	7590 05/28/200 lander	EXAMINER		
Fulbright & Jav		LIU, SAMUEL W		
Suite 2400 600 Congress A	venue		ART UNIT	PAPER NUMBER
AUSTIN, TX 7			1656	
			MAIL DATE	DELIVERY MODE
			05/28/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/791,219	WEISMAN, LOIS			
Office Action Summary	Examiner	Art Unit			
	SAMUEL W. LIU	1656			
The MAILING DATE of this communication Period for Reply	appears on the cover sheet with the	e correspondence address			
A SHORTENED STATUTORY PERIOD FOR REWHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory per - Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the material patent term adjustment. See 37 CFR 1.704(b).	EDATE OF THIS COMMUNICATION 1.136(a). In no event, however, may a reply be id will apply and will expire SIX (6) MONTHS fratute, cause the application to become ABANDO	ON. timely filed om the mailing date of this communication. NED (35 U.S.C. § 133).			
Status					
1) ☐ Responsive to communication(s) filed on OS 2a) ☐ This action is FINAL . 2b) ☐ T 3) ☐ Since this application is in condition for allow closed in accordance with the practice under	his action is non-final. wance except for formal matters, p	prosecution as to the merits is			
Disposition of Claims					
4) Claim(s) 18-26 and 33-58 is/are pending in 4a) Of the above claim(s) 18,19 and 24-26 is 5) Claim(s) 18 and 19 is/are allowed. 6) Claim(s) 24-26 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and Claim(s) are subject to restriction and Claim(s) The specification is objected to by the Exame	s/are withdrawn from consideratio	n.			
10) The drawing(s) filed on is/are: a) applicant may not request that any objection to the Replacement drawing sheet(s) including the cortain th	accepted or b) objected to by the drawing(s) be held in abeyance. Strection is required if the drawing(s) is	See 37 CFR 1.85(a). objected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summa Paper No(s)/Mail 5) Notice of Informa 6) Other:	Date			

Application/Control Number: 10/791,219 Page 2

Art Unit: 1656

DETAILED ACTION

Status of the claims

Claims 18-26 and 33-58 are pending.

Applicant is advised that the Office action ("Final") mailed 6/1/07 is vacated. The

following Office action is applied.

The amendment filed 5/5/08 which cancels claims 1-17, 27-32 and 59-60, and amends

claims 24-26 has been entered. Also, the applicant's request (filed 5/5/08) for extension of time

of three months has been entered. Claims 33-58 remain withdrawn from further consideration.

Claims 18-19 and 24-26 are examined in this Office action.

Withdrawal of objection and rejections

• The objections to claims 18-19 is withdrawn in light of the amendment to claim 18

which delete "non human Vac14 AA" (see the applicants' amendment filed 3/20/07 and the

amendment filed 5/5/08).

• The rejection of claims 24-26 under 35 USC 112, second paragraph is withdrawn in

light of the amendment to claim 24.

• The rejections of claims 24-26 under 35 USC 112, first paragraph (Written description

and Scope enablement) are withdrawn in light of that the applicant's arguments set forth in the

response filed 12/03/07 and the "Appeal brief" filed 5/5/08" are persuasive.

• The rejection of claims 24-26 under 35 USC 102(e) by Robert et al. is withdrawn in

light of the amendment of claims 24-26.

New-Claim Rejections - 35 USC §103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 24-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Drmanac et al. (WO 0175067 A2).

In patent claim 20, Drmanac et al. disclose an isolated polypeptide of SEQ ID NO:51018 which amino acid residues 90-163 has sequence identity to residues 23-96 of instant SEQ ID NO:3 (see the "attachment" labeled "10791219 SEQ Align"). Also, at page 9, lines 12-20, Drmanac et al. further teach a fragment of the disclosed polypeptide wherein said "fragment" is preferably at least 17 amino acids, which is applied to claim 24.

Because Drmanac et al. teach that the "fragment" is preferably 17 or more amino acids (see page 9, lines 16-17); this encompasses peptide fragments of 20 or 25 or 30 residues in length; and thus, said "fragment" is an obvious variation of instant "oligopeptide" of claims 25 and 16.

Although Drmanac et al. do not expressly or directly disclose the oligopeptide comprising 15 consecutive residues of instant SEQ ID NO:3, it would have been obvious to one of ordinary skill in the art that the fragment can be 15, 20, 25 or 30 residues in length. This is because Drmanac et al. have taught that the "fragment" is preferably at least 17 amino acids and preferably less than 100 amino acid (page 9, lines 16 and 18). Within this narrow range: $15 \le \text{length} \le 100$ (note that the "oligopeptide" of claim 24 is in a range of length "between 15 and 30 residues"), with the aid of a computer, one skilled in the art would have readily made the

Application/Control Number: 10/791,219 Page 4

Art Unit: 1656

oligopeptides which have immunological activity (see page 9, line 20) and which have obviously

included those consisting of 15, 20, 25 or 30 residues in length with reasonable expectation of

success.

Conclusion

Claims 17-18 are free from prior art, and claims 24-26 are not allowed.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Samuel Wei Liu whose telephone number is 571-272-0949. The

examiner can normally be reached from 9:00 a.m. to 5:00 p.m. on weekdays. If attempts to reach

the examiner by telephone are unsuccessful, the examiner's supervisor, Kathleen Kerr Bragdon,

can be reached on (571) 272-0931. The fax phone number for the organization where this

application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval IPAIRI system. Status information for published applications may

be obtained from either Private PAIR or Public PAG. Status information for unpublished applications

is available through Private PAG only. For more information about the PAN system, see http://pair-

direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the

Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Samuel W Liu, Ph.D./

Examiner, Art Unit 1656

May 21, 2008

/Karen Cochrane Carlson, Ph.D./

Primary Examiner, Art Unit 1656

Application/Control Number: 10/791,219

Page 5

Art Unit: 1656